Bharat Serums & Vaccines to invest Rs 200 cr in specialty injectables production campus in Hyderabad

Sep 21,2023

HYDERABAD: Bharat Serums and Vaccines Limited (BSV) is investing Rs 200 crore in setting up a global specialty injectables manufacturing facility in Hyderabad’s Genome Valley for which it broke ground on Thursday.

The complex injectables facility, which will cater to the domestic as well as exports to over 80 countries globally including regulated markets, is coming up on a 10-acre parcel of land with the first phase of the project to be ready for production in early 2026, BSV managing director & CEO Sanjiv Navangul told TOI.

“The entire project will be ready in another four years and will provide only about 200-300 jobs as it will be a highly automated plant,” he said, adding that it will manufacture women’s health products, emergency products such as anti-snake venom and rabies injections, immunoglobulins, hormones and even vaccines.

The facility is slated to significantly ramp up the company's capacity in producing injectables with the commissioning of the fill-finish formulation line in phase-1 and an additional multi-product line in phase-2 of the project.

The manufacturing facility will produce products adhering to international quality systems while complying to the Indian regulatory norms of Schedule M as well as global regulatory requirements, the company said.

“We will have a general line, a complex injectables line, a hormones line and some space for an additional line to produce vaccines. We need to determine what kind of vaccines can be made here,” Navangul said.

BSV currently has a manufacturing facility in Ambernath in Maharashtra catering to domestic as well as over 80 export markets, and an API (active pharmaceutical ingredients) manufacturing facility in Aachen, Germany, that serves the international markets.

Source: Times of India